Anzeige
Mehr »
Login
Freitag, 22.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14WZY | ISIN: US9034801012 | Ticker-Symbol: UNC0
Siehe auch UCB SA
Frankfurt
21.11.24
08:02 Uhr
83,50 Euro
+2,00
+2,45 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
UCB SA ADR Chart 1 Jahr
5-Tage-Chart
UCB SA ADR 5-Tage-Chart

Aktuelle News zur UCB SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiFDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease5
MiRapid growth spurt for UCB's Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approval5
MiUCB gets FDA approval for Bimzelx for hidradenitis suppurativa4
MiUCB's BIMZELX Approved by FDA for Treatment of Adults with Hidradenitis Suppurativa3
MiUCB Reports FDA Approval Of BIMZELX In Moderate-to-severe Hidradenitis Suppurativa-
MiUCB's Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults1
UCB SA ADR Aktie jetzt für 0€ handeln
MiUCB Receives U.S. FDA Approval for BIMZELX (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa89Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which BIMZELX® (bimekizumab-bkzx) improved the signs and symptoms of...
► Artikel lesen
MiUCB Receives US FDA Approval For Bimzelx7
DiBiogen, UCB release phase 3 data on lupus candidate dapirolizumab21
DiUCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study268WESTON (dpa-AFX) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant...
► Artikel lesen
DiUCB Presents Dapirolizumab Pegol Phase 3 Data4
08.11.GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more27
06.11.UCB stock hits 52-week high at $31.98 amid robust growth9
05.11.UCB (OTCMKTS:UCBJY) Sets New 12-Month High - What's Next?12
05.11.UCB shares 'encouraging' data for Alzheimer's disease candidate bepranemab13
01.11.UCB's tau drug flunks phase 2 Alzheimer's trial days after Roche's exit from $120M bet48
22.10.Roche tosses out tau prospect, returning rights to UCB 4 years after placing $120M bet32
07.10.DelveInsight Business Research, LLP: The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight564UCB and Biogen reported encouraging topline findings from the Phase III PHOENYCS GO trial, which assessed dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in individuals with...
► Artikel lesen
04.10.Warnung vor Dosierfehlern!: Neue Spritze für Keppra und Levetiracetam UCB11
27.09.UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa9
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1